Cancer Immunology – News and Features

Researchers have uncovered a new pathway that enables cancer cells to grow unchecked by disabling the immune system.

A newly described stage of a lymph node-like structure seen in liver tumors after presurgical immunotherapy may be vital to successfully treating patients with hepatocellular carcinoma.

Researchers at Weill Cornell Medicine identified a mechanism by which ovarian tumors inhibit T cell lipid uptake, impairing immune response. By modifying the Transgelin 2 gene in CAR T cells, they enhanced their effectiveness against ovarian tumors.

Scientists have engineered CAR-T cells with on/off switches activated by existing drugs, enhancing safety in cancer therapy. This innovative approach allows for controlled responses to tumor antigens.

Researchers found that cancer cells can modify their ribosomes to enhance their ability to hide from the immune system. By increasing ribosomes with a flexible arm, cancer cells reduce surface protein exposure.

A study reveals a mechanism that controls B-lymphocyte maturation, with SIRT7 playing a critical role. This insight could lead to new treatments for B-cell Acute Lymphoblastic Leukaemia (B-ALL).

A case report highlights a 51-year-old man with stage IV non-small cell lung cancer and brain metastasis who received whole brain radiotherapy followed by immune checkpoint inhibitor treatment.

Researchers link NBR1 protein levels in liver cancer to immunotherapy effectiveness. High NBR1 may indicate poor response to treatment, while lowering NBR1 shrinks tumors in mice.

Researchers have developed an immunotherapy for advanced Hodgkin lymphoma that increased survival rates to 92 percent. This innovative approach reduces long-term side effects associated with traditional treatments.

Researchers have created engineered probiotic bacteria that educate the immune system to attack cancer cells, showing promising results in mouse models. These personalized bacterial vaccines could lead to effective treatments for advanced cancers.